Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWHFree Report) in a research report released on Monday morning. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners reduced their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Get Our Latest Report on AWH

Aspira Women’s Health Stock Performance

AWH opened at $0.75 on Monday. The stock has a market capitalization of $12.50 million, a PE ratio of -0.62 and a beta of 1.44. The stock’s 50 day moving average price is $0.84 and its 200-day moving average price is $1.29. Aspira Women’s Health has a 52-week low of $0.67 and a 52-week high of $5.65.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new position in Aspira Women’s Health Inc. (NASDAQ:AWHFree Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health at the end of the most recent reporting period. 12.19% of the stock is owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.

Featured Articles

Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.